Latest Headlines

31. XtalPi And Pfizer Expand Strategic Collaboration To Advance AI-Driven Drug Discovery And Materials Science Simulations 6/29/2025

    XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with Pfizer to pioneer a next-generation molecular modeling platform for drug discovery.

32. St. Jude Algorithm Puts Water To Work In Drug Discovery 6/27/2025

    Every protein in the body is encased in a water shell that directs protein structure, provides vital stability and steers function. Because of this, water molecules represent a powerful but largely underappreciated foothold in drug binding studies.

33. Cancer Drug Candidate Developed Using Supercomputing & AI Blocks Tumor Growth Without Toxic Side Effect 6/26/2025

    A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics) and the Frederick National Laboratory for Cancer Research (FNLCR) has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect.

34. Grace Therapeutics Announces Submission Of New Drug Application To U.S. Food And Drug Administration For GTx-104 6/25/2025

    Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced the submission to the U.S. Food and Drug Administration (FDA) of the Company’s New Drug Application (NDA) for GTx-104.

35. Scientists Find New Way To Predict How Bowel Cancer Drugs Will Stop Working 6/25/2025

    Scientists have developed a tool that can predict how bowel cancer adapts to treatment - helping researchers to design new personalised drugs that will keep patients living well for longer.

36. Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements With Cambrex And Thermo Fisher Scientific For Drug Substance And Drug Product Supply 6/25/2025

    Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the treatment of Alcohol Use Disorder (AUD) in the US.

37. CARsgen Therapeutics Announces NDA Acceptance Of Satri-cel By China's NMPA 6/25/2025

    CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy.

38. Riliprubart Earns Orphan Drug Designation In The US For Antibody-Mediated Rejection In Solid Organ Transplantation 6/25/2025

    The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation.

39. A Glowing Biosensor For High-Throughput Drug Screening 6/24/2025

    Drug discovery can be a long and complex process. Medicines for neurodegenerative diseases like Alzheimer’s Disease are among the most expensive to develop, as animal model results have not proven to be predictive of efficacy in humans. Scientists usually have to screen many biological targets before identifying a single potential new drug.

40. Causaly Launches AI-Powered Competitive Intelligence Application For Research Scientists 6/24/2025

    Causaly today announced Pipeline Graph, giving life sciences research and development teams a more effective and efficient way to do competitive intelligence earlier in drug discovery.